---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-24-000042"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:17:22.100237+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inspire Q2 revenue $195.9M (+30% YoY), EPS $0.32; raises FY guide, authorizes $150M buyback

## Summary
- Q2 revenue $195.9M (30% YoY), net income $9.8M vs loss $12.0M; diluted EPS $0.32 vs ($0.41).
- FY 2024 revenue guidance raised to $788-798M (26-28% growth); EPS guidance raised to $0.60-0.80 from $0.10-0.20.
- Board authorized $150M share repurchase program, first in company history, expiring August 5, 2026.
- Received FDA approval for Inspire V neurostimulation system and EU MDR CE Mark for full-body MRI compatibility.
- Activated 81 new U.S. centers in Q2 (total 1,316) and added 12 sales territories (total 310).

## SEC filing metadata
- accession: 0001609550-24-000042
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955024000042/0001609550-24-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955024000042/insp-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-24-000042
- JSON: https://secwatch.observer/filing/0001609550-24-000042.json
- Plain text: https://secwatch.observer/filing/0001609550-24-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.